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Introduction
Undernutrition is common in patients admitted with
stroke, nutritional status can deteriorate in hospital, and
undernutrition shortly after admission is independently
associated with increased case fatality and poor
functional status at 6 months.1–7 To compound the
problem, up to half of stroke patients in hospital have
dysphagia, which precludes safe oral nutrition for the
first few days and can persist for long periods.8–10 Surveys
of feeding practice after stroke have recorded much
variation between hospitals in the UK, especially in the
timing of the start of enteral tube feeding and whether a
nasogastric or percutaneous endoscopic gastrostomy
(PEG) tube is used.11 Some clinicians delay tube feeding
for 2 weeks or more. Although early nutrition is unlikely
to be harmful, whether any nutritional benefits offset the
difficulties and complications of initiating and main-
taining early enteral tube feeding is unclear. 
Moreover, difficulties with nasogastric feeding in
stroke patients, who are often confused and
uncooperative, has led to increasing use of PEG tubes at
an early stage. Enthusiasm for this method has been
encouraged by the results of a small single-centre
randomised controlled trial12 that reported much lower
case fatality rates in patients fed via PEG (13%) rather
than nasogastric tube (57%). If the timing or route of
enteral tube feeding does affect outcome, the present
variation in practice means that large numbers of
patients are being denied best treatment. In the FOOD
trials, which included two pragmatic randomised trials of
dysphagic patients, we aimed to answer two main
questions: (1) does early initiation of enteral tube feeding
improve outcomes (early versus avoid trial); and (2) does
enteral tube feeding via PEG rather than nastrogastric
tube improve outcomes (PEG versus nasogastric trial)?
Methods
Trial design and participants
The FOOD trials consisted of three randomised
controlled trials, which shared the same randomisation,
data collection, and follow-up systems, and allowed co-
enrolment. The two trials reported here enrolled patients
with dysphagia. Eligibility criteria were broad: any
patient admitted to a participating hospital with a recent
(within 7 days before admission) stroke (first-ever or
recurrent) could be enrolled if the responsible clinician
was uncertain of the best feeding policy and the patient
or a relative consented. Patients with subarachnoid
haemorrhage were excluded. The FOOD trials were
approved by the multicentre research ethics committee
in the UK and by each centre’s local research committee.
Procedures
Baseline data were acquired during a telephone call to the
international coordinating centre at trial entry (table 1).
Only when all baseline data had been entered and
automatically checked did the computer give out a
treatment allocation. Thus, baseline data were 100%
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Summary
Background Undernutrition is common in patients admitted with stroke. We aimed to establish whether the timing
and route of enteral tube feeding after stroke affected patients’ outcomes at 6 months.
Methods The FOOD trials consist of three pragmatic multicentre randomised controlled trials, two of which
included dysphagic stroke patients. In one trial, patients enrolled within 7 days of admission were randomly
allocated to early enteral tube feeding or no tube feeding for more than 7 days (early versus avoid). In the other,
patients were allocated percutaneous endoscopic gastrostomy (PEG) or nasogastric feeding. The primary outcome
was death or poor outcome at 6 months. Analysis was by intention to treat.
Findings Between Nov 1, 1996, and July 31, 2003, 859 patients were enrolled by 83 hospitals in 15 countries into the
early versus avoid trial. Early tube feeding was associated with an absolute reduction in risk of death of 5·8% (95% CI
–0·8 to 12·5, p=0·09) and a reduction in death or poor outcome of 1·2% (–4·2 to 6·6, p=0·7). In the PEG versus
nasogastric tube trial, 321 patients were enrolled by 47 hospitals in 11 countries. PEG feeding was associated with an
absolute increase in risk of death of 1·0% (–10·0 to 11·9, p=0·9) and an increased risk of death or poor outcome of
7·8% (0·0 to 15·5, p=0·05).
Interpretation Early tube feeding might reduce case fatality, but at the expense of increasing the proportion surviving
with poor outcome. Our data do not support a policy of early initiation of PEG feeding in dysphagic stroke patients.
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complete and treatment allocation was concealed until it
was given. The randomising clinicians were also asked to
confirm that consent had been obtained and to categorise
patients as undernourished, normal, or overweight, on
the basis of their own bedside assessment or, where
practical, a fuller assessment that might include weight,
height, dietary history, or blood tests.7,13,14
A computer-generated minimisation algorithm
balanced treatments within each country, and used age
(75, 75 years), sex, and predicted probability of poor
outcome (80%, 80%) as stratification variables. The
predicted probability was based on a well validated and
reliable model consisting of six variables (age, prestroke
independence, prestroke living alone, ability to lift both
arms off the bed, ability to walk independently, and ability
to talk without being confused).15–18 The details of all
enrolled patients were kept securely in our coordinating
centre to allow proper intention-to-treat analysis.
In the early versus avoid trial, patients were allocated
to start enteral tube feeding (via the clinician’s preferred
tube) as soon as possible or to avoid any enteral tube
feeding for at least 7 days. Patients who were not tube
fed were given parenteral fluids either intravenously or
subcutaneously, but not nutrition. In the PEG versus
nasogastric trial, patients were allocated to enteral tube
feeding via PEG or nasogastric tube within 3 days of
enrolment. The allocated method was continued as long
as it remained practical, or as the patient’s condition
dictated. Patients in both groups of both trials were kept
nil by mouth when the team felt this was necessary, but
could be fed orally (instead of or in addition to tube
feeding) if their swallowing ability improved. The
randomising clinician, the clinical team, and the
patients were not unaware to treatment allocation—
doing so would have been impossible.
If the clinician was uncertain whether to start enteral
tube feeding within 7 days of admission, the patient was
enrolled into early versus avoid. The clinician could, if he
or she wished, choose the type of tube. If during the first
30 days of admission the clinician was uncertain
whether to insert a PEG or nasogastric tube (or to
continue with an existing nasogastric tube), the patient
could be enrolled into the PEG versus nasogastric trial.
If the clinician was uncertain about both timing and type
of tube feeding, patients could be co-enrolled at the same
time (ie, if allocated early feeding the patient was
randomly allocated to PEG or nasogastric tube) or at
different times (eg, enrolled into PEG versus nasogastric
trial after the end of the 7-day period of avoiding tube
feeding in early versus avoid trial).
After discharge or in-hospital death, the local
coordinator completed a hospital discharge form and, on
the basis of a review of the case notes, recorded the start
and finish dates of any enteral tube feeding or parenteral
fluids, the route of enteral feeding, the number of tubes
inserted, the types of food given, whether the clinician
felt that enteral feeding had been satisfactory, the reasons
for stopping, and any complications of feeding or of
stroke. They recorded only complications that occurred
after randomisation and before discharge or in-hospital
death. This review was not explicitly done unaware of
baseline nutritional status or treatment allocation. Data
were audited centrally to check for completeness and
internal consistency, and to ensure that they conformed
to expected values and distributions.
Follow-up aimed to establish patients’ vital status,
functional ability with the modified Rankin score (MRS),19
place of residence, method of feeding, and quality of life
with the EUROQoL.20 The MRS grades patients from
grade 0 (no symptoms) to grade 5 (requiring constant
attention day and night). Each national coordinating
centre obtained follow-up information 6 months after
enrolment, mainly masked to treatment allocation,
usually by means of a postal questionnaire or structured
telephone interview. If patients were unable to provide
information, it was acquired from a carer or proxy. Some
patients in Singapore and India were followed up in an
outpatient clinic or at home by a masked assessor. Thus
follow-up was masked to treatment allocation (except
where patients or carers inadvertently unmasked an
interviewer at follow-up; such occurrences were unusual
but their frequency was not systematically recorded). 
Sample size calculations were based on a dichotomous
outcome, dead or poor outcome at follow-up. The cut-off
Early tube Avoid tube PEG tube Nasogastric tube
Randomly allocated 429 430 162 159
Male 195 (45%) 199 (46%) 73 (45%) 71 (45%)
Age (years) (mean, SD) 76 (11) 76 (11) 76 (10) 76 (10)
Independent ADL before stroke 354 (83%) 358 (83%) 135 (83%) 126 (79%)
Lived alone 112 (26%) 120 (28%) 57 (35%) 50 (31%)
Can lift both arms 75 (17%) 63 (15%) 24 (15%) 27 (17%)
Walks unaided 16 (4%) 11 (3%) 4 (2%) 6 (4%)
Glasgow coma scale verbal normal 112 (26%) 117 (27%) 40 (25%) 40 (25%)
Predicted poor outcome*
Mildest tertile 152 (35%) 140 (33%) 49 (30%) 48 (30%)
Moderate tertile 145 (34%) 142 (33%) 59 (35%) 59 (37%)
Most severe tertile 132 (31%) 148 (34%) 54 (33%) 52 (33%)
Baseline nutritional status
Undernourished 34 (8%) 40 (9%) 36 (22%) 34 (21%)
Normal 313 (73%) 308 (72%) 96 (59%) 100 (63%)
Overweight 82 (19%) 82 (19%) 30 (19%) 25 (16%)
Country (four most common)
UK 235 (55%) 233 (54%) 130 (80%) 130 (82%)
Italy 64 (15%) 65 (15%) .. ..
New Zealand 37 (9%) 34 (8%) 6 (4%) 3 (2%)
Singapore 34 (8%) 33 (8%) 9 (6%) 8 (5%)
Czech Republic .. .. 7 (4%) 5 (3%)
Diagnosis†
Conﬁrmed stroke 427 (99%) 426 (99%) 162 (99%) 159 (99%)
Brain tumour 1 (1%) 1 (1%)
Other non-stroke 1 (1%) 1 (1%)
Delay from stroke to randomisation‡ 2 (1–4) 3 (1–4) 8 (4–13) 7 (5–12)
Delay from admission to randomisation‡ 2 (1–4) 2 (1–4) 8 (4–13) 7 (4–12)
Data are number (%) unless otherwise indicated. ADL=activities of daily living. *Based on validated statistical model with six
variables. †Final diagnosis of prerandomisation event recorded on hospital discharge form. ‡Median (IQR). Forms received for
429 patients in early tube group, and 428 in no tube group. Discharge forms received for all other patients.
Table 1: Baseline characteristics of patients
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value for poor outcome was MRS grade 4–5 in these
trials, compared with grade 3–5 in our other trial,13
because a grade of 3 in a dysphagic patient would be
regarded as a good outcome in view of the associated
severity of stroke. Our two primary outcomes were death
or poor outcome and overall survival, subdivided by
allocated treatment, irrespective of compliance.
Other outcomes, which were obtained masked to
treatment allocation, included place of residence and
EUROQoL score (from which a utility score was
derived21). Other secondary outcomes that were not
obtained masked to allocation were compliance with
treatment, length of hospital stay, and in-hospital
complications and causes of death. We planned to
examine treatment effects on our primary outcomes
subdivided by  baseline nutritional status, baseline
prognosis, and (in the PEG versus nasogastric trial only)
time between stroke onset and randomisation. We also
examined treatment effect by age at enrolment.
Five interim analyses were prepared by the trial
statistician and presented to the independent data
monitoring committee which, based on its
interpretation of these data, advised the steering group
whether or not it was reasonable to continue to enrol
patients. No explicit stopping rules had been set, but if
the committee felt that there was proof beyond
reasonable doubt for all, or some, that either a treatment
was indicated or contraindicated, or if information that
would materially alter clinical practice emerged, they
would advise the steering committee accordingly.
Reasonable doubt was not defined, but the committee
agreed that a difference of three standard errors in death
or poor outcome (ie, death or MRS 4–5)—equivalent to
about p=0·001)—would probably be necessary before
they would advise stopping the trial prematurely. Only
the trial statistician and members of the data monitoring
committee were aware of these analyses.
The steering committee decided to stop the trials
before we had reached our targets because no funding
was available to continue beyond 2004 and they wished
to ensure that the trials were closed in an orderly
manner. Our decision to stop was not based on any
knowledge of any interim analysis—indeed the data
monitoring committee had recommended continuation
if at all possible.
Centres were not paid to participate, and most did so
without any financial support. We provided some UK
centres that were allocating many patients with modest
resources to help with enrolment and completion of
discharge forms. National coordinating centres were
given enough resources to cover their expenses—eg,
telephone calls, travel, and stationery. From time to
time, we ran recruitment drives during which we offered
modest prizes (support to travel to a coordinators’
meeting or a contribution to ward funds) to centres that
recruited most patients by a particular time. 
Statistical methods
We aimed to recruit 2000 patients in the early versus
avoid trial, which would have provided 81% power to
detect an absolute risk difference of 6% (p=0·05,
two-sided) if 64% in the early group and 70% in the
avoid group were dead or had a poor outcome (MRS
4–5). We planned to enrol 1000 patients in the PEG
versus nasogastric trial, which would have provided 85%
power to detect an absolute risk difference of 9%
(p=0·05, two-sided) if 61% allocated PEG and 70%
allocated nasogastric tube were to die or have a poor
Clinician uncertain
when to start tube
feeding
52 enrolled into
both trials at same time
28 were coenrolled a
median 9 days later
Median delay
to follow-up
6·8 months
(IQR 6·0–8·3)
Median delay
to follow-up
6·5 months
(IQR 5·8–7·8)
Median delay
to follow-up
6·2 months
(IQR 5·7–7·5)
Median delay
to follow-up
6·6 months
(IQR 5·8–7·7)
Admission with acute stroke
and failed swallow screen
Clinician uncertain
whether to use PEG
or nasogastric tube
Clinician chooses
to start tube
feeding
859 randomly
         assigned 
321 randomly
         assigned 
429 allocated
         early tube
  Clinician choice:
  367 nasogastric
     10 PEG
  Randomised:
     26 nasogastric
     26 PEG
429 discharge
         forms
         available
429 follow-up
         forms
         available
182 dead
247 alive
207 dead
223 alive
1 lost to
   follow-up
428 discharge
         forms
         available
430 follow-up
         forms
         available
162 follow-up
         forms
         available
   79 dead
   83 alive
   76 dead
   83 alive
159 follow-up
         forms
         available
430 allocated
         avoid tube 
162 allocated
         PEG
159 allocated
         nasogastric
162 discharge
         forms
         available
159 discharge
         forms
         available
Figure 1: Trial proﬁles
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outcome (MRS 4–5). Primary analyses were by intention
to treat. The proportions of patients in each group with a
dichotomous outcome (eg, who were dead or had a poor
outcome) were compared with odds ratios and 95% CIs
derived from unadjusted logistic regression. For death
and in-hospital complications, Kaplan-Meier survival
curves were constructed and the significance of any
differences assessed with the log-rank test. Utilities
derived from EUROQoL were compared with the
Wilcoxon two-sample test. We calculated p values for
subgroup analyses from the change in log likelihood
when the interaction between treatment and subgroup
of interest was entered into a logistic regression model.
Role of the funding source 
The sponsors had no role in study design, data
collection, data analysis, data interpretation, or writing
the report. The corresponding author had full access to
all the data in the study and had final responsibility for
the decision to submit for publication. 
Results
Between Nov 1, 1996, and July 31, 2003, 83 hospitals in
15 countries enrolled 859 patients in the early versus
avoid trial (participating centres and numbers of patients
enrolled listed at end of report). 47 hospitals in
11 countries enrolled 321 patients in the PEG versus
nasogastric trial; 80 (25%) had also been co-enrolled in
the other trial, 52 at the same time (figure 1). Data about
compliance, in-hospital complications, and follow-up
were obtained until March 31, 2004, when the database
was closed. Table 1 shows patients’ baseline
characteristics. 
Baseline data were 100% complete. Discharge forms
and follow-up forms were available for more than 99% of
patients enrolled. Figure 1 shows the flow of patients
through the trial. A few patients did not receive the
allocated treatment for several reasons: inability to insert
tubes, change of mind by clinicians or patients, logistic
problems accessing PEG insertion within the 3 days
specified in the protocol, administrative mistakes, and
poor communication. 
In the early versus avoid trial, of the 430 patients
allocated to avoid tube feeding, 58 (13%) received tube
feeding within 7 days of randomisation. Of the
429 patients allocated early tube feeding, 60 (14%) did
not receive a tube within 3 days. In the PEG versus
nasogastric trial, of 159 patients allocated nasogastric
tube, 137 (86%) received this treatment (including
44 who were later swapped to a PEG tube). Of the others,
nine received no tube feeding, and 13 received only PEG
tube feeding. Only this last group are strictly cross-overs
to the other treatment. Of the 162 patients allocated PEG
tube, 78 (48%) received this tube within 3 days, and 115
(71%) received this tube before any nasogastric tube. Of
the others, 21 received neither nasogastric nor PEG tube
feeding, 17 received a nasogastric then a PEG tube, and
nine received only nasogastric tube feeding. Only these
last two groups are strictly cross-overs to the other
treatment. 
Figure 2 shows the proportion of patients starting their
allocated feeding regimen during the first month after
randomisation. Figure 3 shows the proportions receiving
enteral feeding via a nasogastric or PEG tube while in
hospital, the proportions receiving neither (ie, oral diet or
parenteral fluids only), the proportion who had been
discharged or had died during the first 6 months after
randomisation in each group of the two trials. Any
differences in outcomes should be attributable to the
differences between these patterns of feeding. The
numbers and proportion of enrolled patients who died
and the MRS of survivors in each group are shown in
table 2 and figure 4. Survival did not differ significantly
between the treatment groups, although the early versus
avoid curves seem to diverge at about 2 months after
enrolment (log-rank test p=0·14; figure 5).
In the early versus avoid trial, allocation to early tube
feeding was associated with a non-significant reduction
in absolute risk of death of 5·8% (95% CI –0·8 to 12·5,
p=0·09). The absolute reduction in risk of death or poor
outcome was in the same direction but much more
modest (1·2%, –4·2 to 6·6, p=0·7). In the PEG versus
nasogastric trial, allocation to PEG feeding was
associated with a non-significant increase in the absolute
risk of death of 1·0% (–10·0 to 11·9, p=0·9) but an
increase of borderline significance in absolute risk of
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Figure 2: Allocated and received method of feeding during ﬁrst month after
randomisation 
(A) early versus avoid and (B) PEG versus nasogastric trial.
Articles
768 www.thelancet.com Vol 365   February 26, 2005 
death or poor outcome of 7·8% (0·0% to 15·5%,
p=0·05).
Of the 389 deaths in early versus avoid trial, 12 were
attributed to tube feeding. Of these, five were in the
avoid group, of whom three died after nasogastric
insertion and two after PEG insertion. Of the seven in
the early group, five died after nasogastric insertion and
two after PEG insertion. In the PEG versus nasogastric
trial, three of 76 deaths in the nasogastric group and
eight of 79 in the PEG group were attributed to
treatment. 
In neither trial were there significant differences
between groups in the frequency of recurrent strokes,
neurological worsening, pneumonia, urinary infection,
or venous thromboembolism. However, the rate of
gastrointestinal haemorrhage was higher with early
rather than avoid tube feeding (22 vs 11, p=0·04) and
with nasogastric rather than PEG tubes (18 vs five,
p=0·005). Not all these haemorrhages occurred while
the tube was in place. Of the 33 haemorrhages in the
early versus avoid trial, 19 occurred with a nasogastric
tube in place, four with a PEG tube in place, six after
removal of a nasogastric tube, two after removal of a
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Figure 4: MRS at follow-up
Modiﬁed Rankin Scale Early tube (n=429) Avoid tube (n=430) PEG tube (n=162) Nasogastric tube (n=159)
0 4 (1%) 9 (2%) 2 (1%) 1 (1%)
1 10 (2%) 16 (4%) 0 3 (2%)
2 26 (6%) 19 (4%) 7 (4%) 6 (4%)
3 50 (12%) 41 (10%) 9 (6%) 20 (13%)
4 53 (12%) 42 (10%) 8 (5%) 12 (8%)
5 104 (24%) 95 (22%) 57 (35%) 41 (26%)
Dead 182 (42%) 207 (48%) 79 (49%) 76 (48%)
Unknown 0 1 (1%) 0 0
MRS 0–3 90 (21%) 85 (20%) 18 (11%) 30 (19%)
MRS 4–5 157 (37%) 137 (32%) 65 (40%) 53 (33%)
Dead or MRS 4–5 339 (79%) 344 (80%) 144 (89%) 129 (81%)
Table 2: MRS score, primary outcome, and death
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PEG tube, and two in patients who never had a tube. Of
the 23 haemorrhages in the PEG versus nasogastric trial,
seven occurred during nasogastric feeding, ten during
PEG, four after nasogastric removal, and two in patients
without tubes. Data about the results of investigations of
patients with gastrointestinal haemorrhage were not
acquired systematically. There were more pressure sores
in the PEG than nasogastric group (12 vs four, p=0·04).
However, these data on complications need to be
interpreted with caution because allocated treatment
was not masked, many statistical comparisons were
made, and it was not feasible for local source data to be
verified for the occurrence of complications.
In the early versus avoid trial, discharge information
was available for 429 (100%) in the early group and 428
(99·5%) in the avoid group; the median lengths of
hospital stay were 24 days in both avoid (IQR 12–58) and
early (IQR 12–53) groups. The mean length of stay was
45 days (SD 58) in the early group and 44 days (SD 50) in
the avoid group (difference of means 1·3 days, –8·6 to
5·9). In the PEG versus nasogastric trial, discharge
information was available for all patients. The median
lengths of stay were 34 days (IQR 17–66) in the PEG
group and 37 days (17–76) in the nasogastric group. The
mean lengths of stay were 55 days (SD 68) and 53 days
(SD 52), respectively (difference of means –2·1 days,
95% CI –15·5 to 11·3). There were no significant
differences in the discharge destinations between the
two groups in either trial.
Data for accommodation and feeding method at
6 months’ follow-up were available for all but one patient
in the avoid group (table 3). In the early versus avoid
trial, follow-up data about quality of life (EUROQoL)
were available for 421 (98%) in the early group and 428
(99%) in the avoid group. Median utilities (including
dead patients with a utility of 0) were 0·00 in both
groups (p=0·76, difference in means 0·013, –0·028 to
0·053), but if dead patients were excluded, the utilities
were marginally better for patients in the avoid rather
than early feeding group (0·15 vs 0·08, p=0·35). In the
PEG versus nasogastric tube trial, data were available in
all but one patient (99%) in each group. If dead patients
were excluded, median utility was 0·00 for both groups
(p=0·12, difference of means 0·035, 95% CI –0·024 to
0·093), but when dead patients were excluded the utility
was marginally better in the nasogastric group (0·08 vs
–0·04, p=0·17).
Figure 6 shows primary outcomes by age, baseline
nutritional status, tertiles of predicted stroke outcome,
and time between stroke onset and randomisation (early
randomisation defined as within 7 days of stroke onset
in the PEG versus nasogastric trial). No differences were
apparent in treatment effects between subgroups.
Discussion
We have not shown any significant differences in
outcomes between early enteral tube feeding and
avoidance of it. Nonetheless, there was an absolute
difference in the risk of death in favour of early feeding,
and although this was not significant at the 5% level, the
CIs were precise enough that a clinically significant
hazard from early tube feeding is unlikely. There was
also no excess of pneumonia associated with early tube
feeding, which will reassure many clinicians. However,
the apparently improved survival was offset by the 4·7%
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Figure 5: Kaplan-Meier survival curves
(A) early versus avoid and (B) PEG versus nasogastric tube. 
Early tube feeding Avoid tube feeding PEG tube Nasogastric tube
(n=429) (n=430) (n=162) (n=159)
Living at home 153 (36%) 136 (32%) 35 (22%) 40 (25%)
Living in institution 94 (22%) 86 (20%) 48 (30%) 43 (27%)
PEG tube in place 30 (7%) 23 (5%) 34 (21%) 19 (12%)
Nasogastric tube in place 14 (3%) 10 (2%) 2 (1%) 3 (2%)
Table 3: Accommodation and feeding at 6 months’ follow-up
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excess of survivors with a poor outcome, with worse
quality of life in those allocated early tube feeding. Thus,
early feeding may keep patients alive but in a severely
disabled state when they would otherwise have died. 
In our second trial, PEG versus nasogastric tube, there
was an absolute difference in death or poor outcome in
favour of nasogastric feeding. The CIs were precise
enough that a clinically significant benefit from PEG
rather than nasogastric tube feeding is highly unlikely.
The explanation for this difference is not clear, but one
factor might be the effect of a long-term PEG tube on
dependency, since more patients in the PEG group were
still receiving such tube feeding than in the nasogastric
group at follow-up. The survivors in the PEG group were
also more likely to be living in institutions and had lower
quality of life. Worse outcomes might in part be explained
by the greater delay to first tube feeding in the PEG group
than in the nasogastric group, but the results from the
early versus avoid trial suggest that this would be only a
minor factor, assuming that the results of one trial apply
to the slightly different population enrolled in the other. 
One interesting finding in both trials was the greater
risk of gastrointestinal haemorrhage in those who were
tube fed, and especially those fed via a nasogastric tube.
This might plausibly result from direct trauma to the
gastric mucosa or from aspirin being put down the tube,
but we had insufficient data to explore the mechanism
further. Another intriguing finding was the excess of
pressure sores in the PEG group, raising the possibility
that those with such tubes might move less or be nursed
differently. 
One of this study’s strengths is that it had a fairly large
sample size. It is the first trial to assess the effect of early
enteral tube feeding after stroke, and is only the third
trial comparing PEG and nasogastric feeding after
stroke.12,22 It was ten times larger than any previous trial
comparing these feeding methods in stroke patients.12
Other strengths include recruitment from a wide range
of hospitals in many countries, increasing
generalisability; secure central randomisation with
concealment of allocation; assessment of primary
outcomes unaware of treatment allocation; almost 100%
complete follow-up at 6 months. Weaknesses include
insufficient statistical power to exclude more modest
differences between groups; no information about the
proportion of eligible patients enrolled in each centre;
our use of an informal (although reliable and highly
predictive) assessment of nutritional status; absence of
precise monitoring of patients’ daily intake of nutrients;
absence of on-site source data verification or collection
of information on changing nutritional status (eg, in-
hospital weights); possible bias due to lack of masking of
secondary outcome measures. Although compliance was
not 100%, this fact results from the inevitable difficulties
of adhering to rigid schedules when patients’ conditions
change after randomisation, of the preferences of
clinicians, patients, and families for particular feeding
regimens, and the practical and logistic problems of
instituting and continuing enteral tube feeding.
Early 
n/N (%) 
Avoid
n/N (%)
Odds ratio
(95% CI)
Odds ratio
(95% CI)
p value
A
B
All 339/429 (79%) 344/429 (80%) 0·93 (0·67–1·30)
Normal 248/313 (79%) 247/307 (80%) 0·93 (0·63–1·37) 0·82
Moderate 119/145 (82%) 125/142 (88%) 0·62 (0·32–1·21) 0·16
Overweight 60/82 (73%) 62/82 (76%) 0·88 (0·44–1·78)
Mild 94/152 (62%) 84/140 (60%) 1·08 (0·68–1·73)
Severe 126/132 (95%) 135/147 (92%) 1·87 (0·68–5·12)
75 years 110/174 (63%) 105/164 (64%) 0·97 (0·62–1·51) 0·99
75 years 229/255 (90%) 239/265 (90%) 0·96 (0·54–1·70)
Undernourished 21/34 (62%) 27/40 (68%)
Normal 133/313 (42%) 145/307 (47%)
Overweight 28/82 (34%) 35/82 (43%)
Moderate 58/145 (40%) 72/142 (51%)
Severe 72/132 (55%) 92/147 (63%)
75 years 42/174 (24%) 51/164 (31%)
75 years 140/255 (55%) 156/265 (59%)
All 182/429 (42%) 207/429 (48%)
0·78 (0·30–2·03)
0·83 (0·60–1·13) 0·89
0·70 (0·37–1·31)
0·65 (0·41–1·04) 0·19
0·72 (0·45–1·16)
0·71 (0·44–1·14) 0·53
0·85 (0·60–1·20)
0·79 (0·60–1·03)
Favours early Favours avoid
Mild 52/152 (34%) 43/140 (31%) 1·17 (0·72–1·92)
PEG
n/N (%)
Nasogastric
n/N (%)
p value
35/36 (97%) 30/34 (88%)
85/96 (89%) 79/100 (79%)
24/30 (80%) 20/25 (80%)
37/49 (756%) 28/48 (58%)
56/59 (95%) 52/59 (88%)
51/54 (94%) 49/52 (94%)
51/62 (82%) 47/66 (71%)
93/100 (93%) 82/93 (88%)
54/63 (86%) 54/69 (78%)
Undernourished
Normal
Overweight
Mild
Moderate
Severe
75 years
75 years
Early randomisation
4·67 (0·49–44·05)
2·05 (0·93–4·53) 0·44
1·00 (0·27–3·77)
2·20 (0·93–5·25)
2·51 (0·62–10·23) 0·69
1·04 (0·20–5·41)
1·87 (0·81–4·35) 0·94
1·78 (0·66–4·81)
1·67 (0·67–4·13) 0·78
1·86 (0·99–3·50)
2·00 (0·83–4·83)
Undernourished 22/36 (61%) 20/34 (59%)
45/96 (47%) 46/100 (46%)
12/30 (40%) 10/25 (40%)
16/49 (33%) 14/48 (29%)
35/59 (59%) 29/59 (49%)
28/54 (48%) 33/52 (63%)
23/62 (37%) 22/66 (33%)
56/100 (56%) 54/93 (58%)
33/63 (52%) 32/69 (46%)
46/99 (46%) 44/90 (49%)
Normal
Overweight
Mild
Moderate
Severe
75 years
75 years
Early randomisation
Late randomisation
All 79/162 (49%) 76/159 (48%)
1·10 (0·42–2·86)
1·04 (0·59–1·82) 0·99
1·00 (0·34–2·96)
1·18 (0·50–2·79)
1·51 (0·73–3·13) 0·25
0·62 (0·29–1·35)
1·18 (0·57–2·44) 0·60
0·92 (0·52–1·63)
1·27 (0·64–2·52) 0·46
0·91 (0·51–1·61)
1·04 (0·67–1·61)
Favours PEG Favours nasogastric
Effect on death or poor outcome
Effect on death or poor outcome
Odds ratio and 95% CI
Odds ratio and 95% CI
0 1 2 3 4 5 6 7
Effect on death
Late randomisation 90/99 (91%) 75/90 (83%)
All 144/162 (89%) 129/159 (81%)
Effect on death
Undernourished 31/34 (91%) 35/40 (88%) 1·48 (0·33–6·69)
0 1 2 3 4 5 6 7
Figure 6: Effect of (A) early tube feeding versus avoid tube feeding and (B) feeding via PEG versus nasogastric
tube on both primary outcomes by baseline characteristics
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There are no comparable trials assessing early tube
feeding after stroke. However, a meta-analysis of the
three completed trials comparing PEG and nasogastric
tubes22 estimates that the odds ratio for death is 0·88
(95% CI 0·59–1·33) in favour of PEG. This value is not
significant, and the CIs are wide and include the
possibility of a large advantage or disadvantage with
respect to survival for PEG over nasogastric feeding.
Heterogeneity was moderate (I2=65%) between the three
trials. Insufficient data were available to explore any
other outcomes. It is unclear why the study by Norton
and others12 provided such an optimistic estimate of the
benefits of PEG feeding; no baseline data were
published, so chance imbalance in baseline severity of
stroke within that trial resulting from the small sample
size could be the explanation.
We think that further large randomised controlled
trials addressing these issues are unlikely to be
undertaken in the next few years. So how might these
trials influence clinical practice? Our data would suggest
that to reduce case fatality, unless there is a strong
indication to delay enteral tube feeding (such indications
would have excluded such patients from the FOOD
trial), dysphagic stroke patients should be offered enteral
tube feeding via a nasogastric tube within the first few
days of admission. Also, for enteral feeding within the
first 2 or 3 weeks, nasogastric feeding should be the
chosen route unless there is a strong practical reason to
choose PEG feeding (eg, the patient cannot tolerate a
nasogastric tube). 
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FOOD trials collaboration by country (number of patients randomised in
early versus avoid and PEG versus nasogastric trials, respectively)
Australia—Redcliffe Hospital (1,3): T Bennett, J Karrasch, C Lowe; The
Alfred, Prahran (3,0): A Bramley, J Frayne; Royal North Shore Hospital,
Sydney (1,0): E O’Brien, F Simpson.
Belgium—AZ Sint-Jan AV, Bruges (15,5): V Schotte, C Vandenbruaene,
G T O Vanhooren, C Vanmaele.
Brazil—Hospital Universitario Fraga Filho, Rio de Janeiro (1,4): 
C Andre, M A S D Lima, M O Py. 
Canada—Halifax Infirmary (2,0): S J Phillips, Y Reidy.
Czech Republic—District Hospital, Pardubice (14,12): E Ehler, P Geier,
P Vyhnalek.
Denmark—Hvidovre Hospital (1,2): L Bech, D Rizzi, T Soerensen.
Hong Kong—Ruttonjee Hospital, Wanchai (13,1): K Y Chan,
E S L Chow, C K L Kng, C P Wong.
India—St John’s Medical College Hospital, Bangalore (18,0): Ananadan,
U Devraj, J M Jose, T Manjari, L Pinheiro, A K Roy; All India Institute
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G Benemio, M G Celani, C Ottaviani, B Randolph, S Ricci, A Tufi;
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Ospedale di Pistoia (6,0): D Sita, P Vanni, G Volpi; Ospedale 
“S Maria delle Croci”, Ravenna (5,1): G Bianchedie, G Ciucci; Hospital
Civile, S Vito Al Tagliamento (4,0): A G Gregoris, M L Lorenzet,
Ospedale “Sestilli”–INRCA, Ancona (4,0): M Del Gobbo, O Scarpino; 
M T Tonizzo; Morgagni–Pierantoni Hospital, Forli (3,0): G Benati, 
V Pedone; Ospedale di Todi (3,0): B Bisconttini, A Boccali, 
P Del Sindaco, T Mazzoli; Ospedale Civile, Sassari (2,0): G Casu, 
M F Puggioni; Ospedale Cattinara, Trieste (1,1): L Antonuttie, 
F Chiodo Grandi, N Koscica, G Nider; University la Sapienza, Rome
(2,0): A Falcou, A Gualtieri, M Sorgi; Ospedale Don Calabria, Verona
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(0,1): M Cornia, M A Passaniti; Ospedale S Michele, Cagliari (1,0): 
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New Zealand—Tauranga Hospital (41,2): P Blattmann, A M Chancellor;
Auckland Hospital (29,7): N E Anderson, P J Bennett, A J Charleston,
D A Spriggs; Hawke’s Bay Hospital (1,0): T Frendin, J Gommans,
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Portugal—Hospital Distrital de Oliveira de Azemeis (7,0): E Marques,
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Republic of Ireland—Portiuncula Hospital. County Galway (2,3):
T O’Malley.
Singapore—Singapore General Hospital (67,17): C F Chan, J-M Chang, 
C P L-H Chen, H P A Goh, W Luman, M C Wong.
Turkey—Y´stanbul Medical Faculty (24,0): S Bahar, O Çoban,
M De∂irmencio∂lu, M E Gürol, Y Krespi, Bekir Tu∂cu; 
Baky´rköy Ruh ve Sinir Hastaly´klary´, Y´stanbul (2,0): H Acar, S Baybabp, 
S Kabay, E Seçkin, B Yalçy´ner.
UK—Western General Hospitals, Edinburgh (99,28): M S Dennis,
R Lindley, D Shaw, P Taylor; Northwick Park Hospital, Harrow (96,20):
K Butchard, D L Cohen; Ulster Hospital, Belfast (52,8): J Finnerty,
M J P Power; Brighton General Hospital (25,30): M J Bradshaw,
M Eddleston, Q J Syed, S Kumar; Bishop Auckland General Hospital
(9,40): K V Baliga, A A Mehrzad; Royal Bournemouth and Christchurch
Hospitals (9,34): A Graham, A Hanrahan, D Jenkinson, J Kwan,
S Ragab; St Thomas’s Hospital, London (25,11): A G Rudd, C O’Conner;
Scarborough Hospital (7,22): J Clark, P Davies, K Deighton, J Paterson;
Royal Victoria Hospital, Belfast (20,0): A Hunter, M Watt, I Wiggam;
Burnley General Hospital (3,15): S Davies, M N Gorrah, A Joshi; Royal
Infirmary of Edinburgh (15,1): M Brogan, G Mead; Leeds General
Infirmary (4,5): P Wanklyn; North Bristol NHS Trust (Southmead) (9,0):
T Allain, P Easton, A Russ; Poole Hospital (9,0): M T A Villar, 
A Winson; Princess Margaret Hospital, Swindon (5,4): B Dewan, 
S Kausar, H Newton, A Paddon; University Hospital Aintree, Liverpool
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Hospital (0,3): P Bath, P Berman, D Cohen, C Weaver; Peterborough
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